SYNTARA LIMITED — Director's Dealing 2015

Feb 25, 2015

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PHARMAXIS LTD ABN 75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the followingthe director for the purposes of section	information under listing rule 3.19A.2 and as agent for205G of the Corporations Act.
Name of Director	Gary Jonathan Phillips
Date of last notice	2 December 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.
Date of change	26 February 2015
No. of securities held prior to change	Ordinary shares: 60,000Options over ordinary shares: 3,157,500
Class	Options over ordinary shares
Number acquired
Number disposed	385,000 performance rights250,000 options
Value/ConsiderationNote: If consideration is non‐cash, provide details and estimatedvaluation	Nil - lapse of options and performance rights
No. of securities held after change	Ordinary shares: 60,000Options over ordinary shares: 2,522,500

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Performance rights: Based on a review of Example: on‐market trade, off‐market trade, exercise of options, performance for 2014, the Company lapsed issue of securities under dividend reinvestment plan, participation in buy‐back 385,000 performance rights and vested 315,000 performance rights. Options: Options scheduled to lapse at 30 November 2013 and not advised earlier due to oversight in prior Appendix 3Y filed on 2 December 2013.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non‐cash, provide detailsand an estimated valuation
Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed N/A above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011